31 January 2024 in Cancer Research
Cooperation between primary malignant cells and stromal cells can mediate the establishment of lung metastatic niches. Here, we characterized the landscape of cell populations in the tumor microenvironment in treatment-naïve osteosarcoma using single-cell RNA sequencing and identified a stem cell–like cluster with tumor cell–initiating properties and prometastatic traits. CXCL14 was specifically enriched in the stem cell–like cluster and was also significantly upregulated in lung metastases compared with primary tumors. CXCL14 induced stromal reprogramming and evoked a malignant phenotype in fibroblasts to form a supportive lung metastatic niche. Binding of CXCL14 to heterodimeric integrin α11β1 on fibroblasts activated actomyosin contractility and matrix remodeling properties. CXCL14-stimulated fibroblasts produced TGFβ and increased osteosarcoma invasion and migration. mAbs targeting the CXCL14-integrin α11β1 axis inhibited fibroblast TGFβ production, enhanced CD8+ T cell–mediated antitumor immunity, and suppressed osteosarcoma lung metastasis. Taken together, these findings identify cross-talk between osteosarcoma cells and fibroblasts that promotes metastasis and demonstrate that targeting the CXCL14-integrin α11β1 axis is a potential strategy to inhibit osteosarcoma lung metastasis. Significance: Cooperation between stem-like osteosarcoma cells and fibroblasts mediated by a CXCL14-integrin α11β1 axis creates a tumor-supportive lung metastatic niche and represents a therapeutic target to suppress osteosarcoma metastasis.
18 April 2024 in Bone & Joint Open
Aims: The aim of this study was to investigate the safety and efficacy of 3D-printed modular prostheses in patients who underwent joint-sparing limb salvage surgery (JSLSS) for malignant femoral diaphyseal bone tumours.Methods: We retrospectively reviewed 17 patients (13 males and four females) with femoral diaphyseal tumours who underwent JSLSS in our hospital.Results: In all, 17 patients with locally aggressive bone tumours (Enneking stage IIB) located in the femoral shaft underwent JSLSS and reconstruction with 3D-printed modular prostheses between January 2020 and June 2022. The median surgical time was 153 minutes (interquartile range (IQR) 117 to 248), and the median estimated blood loss was 200ml (IQR 125 to 400). Osteosarcoma was the most common pathological type (n = 12; 70.6%). The mean osteotomy length was 197.53 mm (SD 12.34), and the median follow-up was 25 months (IQR 19 to 38). Two patients experienced local recurrence and three developed distant metastases. Postoperative complications included wound infection in one patient and screw loosening in another, both of which were treated successfully with revision surgery. The median Musculoskeletal Tumor Society score at the final follow-up was 28 (IQR 27 to 28).Conclusion: The 3D-printed modular prosthesis is a reliable and feasible reconstruction option for patients with malignant femoral diaphyseal tumours. It helps to improve the limb salvage rate, restore limb function, and achieve better short-term effectiveness.Cite this article: Bone Jt Open 2024;5(4):317–323.
11 December 2024 in Journal of Cancer Research and Clinical Oncology
Neurotrophic Tyrosine Receptor Kinase (NTRK)-rearranged spindle cell tumors are a category of soft tissue tumors characterized by rearrangements of the NTRK gene family (NTRK1, NTRK2, and NTRK3), which leads to distinct molecular genetics, morphological, and immunophenotypic characteristics. The central feature of these tumors is the fusion of NTRK genes with other genes, resulting in abnormal expression and activation of tropomyosin receptor kinase proteins. In this report, we present the first documented case of an NTRK spindle cell tumor with SPECC1L-NTRK3 fusion located in the thoracic spine. This case underscores the diagnostic and therapeutic importance of next-generation sequencing in identifying tumor-specific genetic alterations and selecting targeted therapies. Following 1 month of entrectinib treatment, the patient experienced considerable tumor shrinkage and symptomatic improvement. For bone-derived NTRK-rearranged spindle cell sarcomas, entrectinib shows promising therapeutic efficacy and should be considered a preferred treatment option.
1 July 2025 in Therapeutic Advances in Medical Oncology
Background: Serum C-reactive protein (CRP) level is frequently considered a prognostic predictor of immunotherapy. However, the prognostic role of the interim serum CRP levels before the third course of immunotherapy (CRP-C3) in patients with metastatic colorectal cancer (mCRC) receiving immunotherapy remains unclear. Objectives: This study aimed to determine the predictive value of CRP-C3 for immunotherapy response and progression-free survival (PFS) and to compare its performance with other biomarkers, such as tumor mutational burden (TMB). Design: We conducted a retrospective cohort study of 205 patients with mCRC who received immunotherapy. Methods: Baseline CRP (CRP-B) and CRP-C3 levels were measured in this retrospective cohort study. Clinicopathological data were retrospectively analyzed using Cox regression analyses to identify independent predictive variables for immunotherapy response and PFS, then summarized in nomograms to predict prognosis. Results: The median PFS periods were 8.47 months in the CRP-C3-low subgroup and 2.47 months in the CRP-C3-high subgroup ( p < 0.001). The objective response rate (ORR) was 40.6% and 8.9%, respectively ( p < 0.001). Although CRP-B failed in the multivariate Cox analysis, CRP-C3 performed exceptionally well, surpassing TMB levels (both p < 0.001). Moreover, a prognostic model combining CRP-C3 and TMB levels could significantly stratify patients with mCRC receiving immunotherapy into low-, intermediate-, and high-risk subgroups ( p < 0.001). Patients from different risk subgroups exhibited significantly different ORR (low- vs intermediate- vs high-risk groups: 59.2% vs 32.5% vs 0%, respectively, p < 0.001) and Kaplan–Meier survival curves ( p < 0.001). Conclusion: This retrospective study indicates a potential association between decreased CRP-C3 levels and improved PFS in patients with mCRC receiving immunotherapy. The combination of CRP-C3 and TMB appeared to enhance predictive performance, suggesting their possible utility as prognostic indicators.
8 January 2026 in Clinical Cancer Research
Purpose: To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in the treatment of desmoid tumors (DT). Patients and Methods: In this investigator-initiated, double-blind, phase III trial, we randomly assigned (in a 2:1 ratio) patients with advanced or refractory DTs to receive either PLD (50 mg/m2 intravenously) or placebo every 4 weeks for six cycles. Crossover from placebo to PLD was permitted upon disease progression. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response and safety. Results: From November 2020 to March 2023, a total of 73 patients were assigned to receive PLD (49 patients) or placebo (24 patients). With a median follow-up of 16.1 months, PLD had a significantly longer PFS over placebo (not reached vs. 4.3 months), with an HR of 0.05 (95% confidence interval, 0.01–0.17; P < 0.001). The 2-year PFS rates were 90.4% with the PLD group and 19.6% with placebo. PFS benefit favored PLD across most prespecified subgroups. The confirmed objective response was observed in 19 (40.4%) patients in the PLD group and in one (4.3%) in the placebo group (P = 0.002). Common grade 3 or higher adverse events with PLD included neutrophil count decreased (10.6%), mucositis oral (6.4%), and white cell decreased (4.3%). Significant between-group differences in certain patient-reported toxicities were observed (P < 0.05). Conclusions: PLD significantly prolonged PFS and induced durable responses compared with placebo, with a favorable safety profile, for patients with progressive or symptomatic DTs. See related commentary by Dossa et al., p. 2127
13 June 2023 in Asian Journal of Surgery